Clariscan

Active Ingredient(s): Gadoterate Meglumine
FDA Approved: * November 1, 2019
Pharm Company: * GE HEALTHCARE
Category: Diagnostic Aid

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Clariscan Overview

Gadoteric acid (gadoterate meglumine, trade names Artirem, Dotarem and Clariscan) is a macrocycle-structured gadolinium-based MRI contrast agent (GBCA). It consists of the organic acid DOTA as a chelating agent, and gadolinium (Gd3+), and is used in form of the meglumine salt (Gadoterate meglumine).[1] The paramagnetic property of gadoteric acid reduces the T1 relaxation time (and to some extent the T2 and T2* relaxation times) in MRI, which is the source of its clinical util...

Read more Clariscan Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Gadoteric_acid

Recent Clariscan Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Gadoterate Meglumine
  • Injection: 0.5mmol/ml
  • Solution: 1.8845gm/5ml (376.9mg/ml), 1.884gm/5ml (376.9mg/ml), 3.769gm/10ml (376.9mg/ml), 37.69gm/100ml (376.9mg/ml), 5.6535gm/15ml (376.9mg/ml), 7.538gm/20ml (376.9mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Clariscan: (1 result)

Sorted by National Drug Code
  • 0407-2943 Clariscan 376.9 mg/ml Intravenous Injection, Solution by Ge Healthcare

Other drugs which contain Gadoterate Meglumine or a similar ingredient: (2 results)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 9 July 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA